文献速递外周动脉疾病

直接口服抗凝药与华法林对高危旁路术后通畅率的影响

Effect of Direct Oral Anticoagulants Versus Warfarin on Patency in High-Risk Bypass Patients.
PubMed 文献 · Ann Vasc Surg · 2022-07-08

单机构回顾性研究纳入2012年1月至2021年6月间44例下肢高危旁路术患者,比较术后直接口服抗凝药(DOAC)与华法林的疗效。DOAC组12个月一期通畅率为83.3%,华法林组为57.1%(P=0.03),两组人口学与术前特征无显著差异。作者认为DOAC可考虑作为华法林的安全替代。

要点

  • DOAC组12个月一期通畅率83.3%,华法林组57.1%(P=0.03)。
  • 两组人口学与术前特征无显著差异,DOAC组冠心病比例显著更高(P=0.03)。
  • 多因素分析显示30天内再干预影响12个月通畅率(P=0.02)。

核心结论

  • 接受下肢高危旁路术并术后使用DOAC的患者,移植物通畅率似乎高于使用华法林者。
  • 由于不良反应发生率低且无需频繁监测,作者认为DOAC可考虑作为高危旁路术后华法林的安全替代。

研究设计与样本

  • 单机构回顾性研究,纳入2012年1月至2021年6月间所有下肢高危旁路术且术前或术后开始使用DOAC或华法林抗凝的患者,共44例(男性28例,平均年龄68.8±10.9岁)。
  • 高危旁路术组包括行股动脉至膝上或膝下旁路联合辅助手术,或膝下旁路使用人工血管或复合静脉导管的患者。

主要发现

  • DOAC组与华法林组的人口学特征和术前特征无显著差异。
  • DOAC组冠状动脉疾病患病率显著高于华法林组(P=0.03)。
  • DOAC组12个月一期通畅率为83.3%,华法林组为57.1%(P=0.03)。
  • 多因素分析显示,30天内再干预与12个月通畅率相关(P=0.02)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of warfarin for anticoagulation in thromboembolic disease has been the mainstay of treatment. Direct oral anticoagulants (DOACs) have demonstrated equivalent anticoagulant effects, without increased bleeding risks or need for frequent monitoring. However, the role of DOACs remains unclear in the setting of replacing warfarin for high-risk peripheral artery disease (PAD) interventions. The purpose of this study is to evaluate the efficacy of DOACs compared to warfarin during the postoperative period in patients that underwent a lower extremity high-risk bypass (HRB). METHODS: The study is a single institution, retrospective review of all lower extremity HRBs between January 2012 and June 2021, who were previously placed on or started on anticoagulation with a DOAC or warfarin. The HRB group included all patients undergoing femoral to above or below knee bypass with an adjunct procedure, or below knee bypass with synthetic or composite vein conduit. All demographics, preoperative factors, and complications were evaluated with respect to DOAC versus warfarin. RESULTS: A total of 44 patients (28 males; average age 68.8 ± 10.9) underwent an HRB during the study period. There were no significant differences in demographics and preoperative characteristics between the 2 groups. Among patient comorbidities, coronary artery disease was found to be significantly higher in patients on DOACs (P = 0.03). The 12-month primary patency rate was 83.3% versus 57.1%, for DOAC versus warfarin respectively (P = 0.03). Multivariate analyses revealed that <30-day reinterventions contribute to 12-month patency (P = 0.02). CONCLUSIONS: Patients who underwent lower extremity HRB with postoperative DOAC appeared to exhibit higher graft patency rates than those who were placed on warfarin. Due to their low incidence of undesirable side effects and the lack of frequent monitoring, DOACs could be considered a safe alternative to warfarin in the postoperative period for patients with HRB.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Meghpara MK, Tong Y, Sebastian A, et al. Effect of Direct Oral Anticoagulants Versus Warfarin on Patency in High-Risk Bypass Patients. Ann Vasc Surg. 2022. PMID: 35810945. doi:10.1016/j.avsg.2022.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。